<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816230</url>
  </required_header>
  <id_info>
    <org_study_id>GC P#03.01.020</org_study_id>
    <nct_id>NCT01816230</nct_id>
  </id_info>
  <brief_title>Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamida Cell ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gamida Cell ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit
      (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in
      Patients with Hematological Malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Umbilical cord blood (UCB) is an alternative stem cell source for hematopoietic stem cell
      transplantations (HSCT) and can be used for the treatment of various life-threatening
      diseases, such as hematological malignancies or genetic blood disorders, in such cases where
      a matched related stem cell donor is not available. However, the major drawback of using
      this valuable stem cells source is the limited cell dose in a single cord blood unit (CBU),
      which was shown to be associated with inadequate hematopoietic reconstitution and high risk
      of transplant-related mortality. To improve outcomes and extend applicability of UCB
      transplantation, one potential solution is ex vivo expansion of UCB-derived stem and
      progenitor cells. NiCord® is a stem/progenitor cell based product composed of ex vivo
      expanded allogeneic UCB cells. NiCord® is based on a novel technology for the ex vivo cell
      expansion of cord blood derived hematopoietic progenitor cells. By increasing the number of
      the short and long-term reconstitution progenitor cells transplanted, NiCord® has the
      potential to enable the broader application of UCB transplantation, and improve the clinical
      outcomes of UCB transplantation.

      The study is designed as a multi center, single arm study, evaluating the safety and
      efficacy of the transplantation of NiCord® to patients with hematological malignancies
      following myeloablative therapy.

      Total study duration is approximately 400 days from the signing of informed consent to the
      last visit one year following transplantation

      The overall study objective is to evaluate the safety and efficacy of NiCord®: single
      ex-vivo expanded cord blood unit transplantation in patients with hematological malignancies
      following myeloablative therapy as follows:

      The main study objectives are to assess the cumulative incidence of patients with
      NiCord®-derived neutrophil engraftment at 42 days following transplantation and to assess
      the incidence of secondary graft failure at 180 days following transplantation of NiCord®
      Ten evaluable patients recruited for the study should be 18-65 years of age, up to a maximum
      of 15 treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the cumulative incidence of patients with NiCord®-derived neutrophil engraftment at 42 days following transplantation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>NiCord®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NiCord®</intervention_name>
    <arm_group_label>NiCord®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Applicable disease and eligible for myeloablative SCT

          -  Patients must have two partially HLA-matched CBUs

          -  Back-up stem cell source

          -  Adequate Karnofsky Performance score or Lansky Play-Performance scale

          -  Sufficient physiological reserves

          -  Signed written informed consent

        Exclusion Criteria:

          -  HLA-matched donor able to donate

          -  Prior allogeneic HSCT

          -  Other active malignancy

          -  Active or uncontrolled infection

          -  Active/symptoms of central nervous system (CNS) disease

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iddo Peleg, MSc. MBA</last_name>
    <phone>+972-2-659-5630</phone>
    <email>iddo@gamida-cell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lill, MD</last_name>
      <phone>310-423-1160</phone>
    </contact>
    <investigator>
      <last_name>Michael Lill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steven and Alexandra Cohen Children's Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Brochstein, MD</last_name>
      <phone>718-470-3460</phone>
    </contact>
    <investigator>
      <last_name>Joel Brochstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Horwitz, MD</last_name>
      <phone>919-668-1045</phone>
      <email>mitchell.horwitz@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navneet Majhail, MD</last_name>
      <phone>216-444-2199</phone>
    </contact>
    <investigator>
      <last_name>Navneet Majhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Maziarz, MD</last_name>
      <phone>503-494-4606</phone>
    </contact>
    <investigator>
      <last_name>Richard Maziarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madan Jagasia, MD</last_name>
      <phone>615-936-8422</phone>
    </contact>
    <investigator>
      <last_name>Madan Jagasia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Hospital Gaslini Scientific Institute</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Frassoni, MD</last_name>
      <phone>+39 (010) 563669</phone>
    </contact>
    <investigator>
      <last_name>Francesco Frassoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Cilloni, MD</last_name>
      <phone>+39 0116705475</phone>
    </contact>
    <investigator>
      <last_name>Daniela Cilloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3503 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaap Jan Boelens, MD</last_name>
      <phone>+31-88-7554003</phone>
    </contact>
    <investigator>
      <last_name>Jaap Jan Boelens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Valcárcel, MD</last_name>
      <phone>34 (934) 893 000</phone>
      <phone_ext>6417</phone_ext>
    </contact>
    <investigator>
      <last_name>David Valcárcel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Sanz, MD</last_name>
      <phone>+34 (96) 386-2709</phone>
    </contact>
    <investigator>
      <last_name>Guillermo Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
